Cannell & Spears’s Biogen BIIB Stock Holding History

Cannell & Spears’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$932K	Buy	5,083 +4	+0.1%	+$737	0.02%	246
2025 Q4	$894K	Hold	5,079	–	–	0.02%	248
2025 Q3	$711K	Buy	5,079 +19	+0.4%	+$2.57K	0.01%	262
2025 Q2	$635K	Buy	5,060 +4	+0.1%	+$498	0.01%	257
2025 Q1	$692K	Buy	5,056 +1	+0%	+$143	0.01%	254
2024 Q4	$773K	Hold	5,055	–	–	0.02%	256
2024 Q3	$980K	Hold	5,055	–	–	0.02%	239
2024 Q2	$1.17M	Sell	5,055 -225	-4%	-$48.9K	0.02%	212
2024 Q1	$1.14M	Hold	5,280	–	–	0.02%	217
2023 Q4	$1.37M	Hold	5,280	–	–	0.11%	78
2023 Q3	$1.36M	Hold	5,280	–	–	0.12%	69
2023 Q2	$1.5M	Hold	5,280	–	–	0.12%	72
2023 Q1	$1.47M	Hold	5,280	–	–	0.13%	73
2022 Q4	$1.46M	Hold	5,280	–	–	0.14%	72
2022 Q3	$1.41M	Hold	5,280	–	–	0.14%	72
2022 Q2	$1.08M	Hold	5,280	–	–	0.1%	89
2022 Q1	$1.11M	Hold	5,280	–	–	0.08%	98
2021 Q4	$1.27M	Hold	5,280	–	–	0.09%	92
2021 Q3	$1.49M	Hold	5,280	–	–	0.11%	79
2021 Q2	$1.83M	Hold	5,280	–	–	0.13%	77
2021 Q1	$1.48M	Hold	5,280	–	–	0.11%	77
2020 Q4	$1.29M	Hold	5,280	–	–	0.11%	84
2020 Q3	$1.5M	Hold	5,280	–	–	0.14%	75
2020 Q2	$1.41M	Hold	5,280	–	–	0.15%	73
2020 Q1	$1.67M	Sell	5,280 -37	-0.7%	-$11.2K	0.2%	62
2019 Q4	$1.58M	Sell	5,317 -59	-1%	-$16.4K	0.17%	51
2019 Q3	$1.25M	Hold	5,376	–	–	0.15%	53
2019 Q2	$1.26M	Hold	5,376	–	–	0.15%	54
2019 Q1	$1.27M	Hold	5,376	–	–	0.16%	55
2018 Q4	$1.62M	Sell	5,376 -15	-0.3%	-$4.79K	0.24%	42
2018 Q3	$1.91M	Sell	5,391 -8	-0.1%	-$2.75K	0.23%	43
2018 Q2	$1.57M	Buy	5,399 +23	+0.4%	+$6.47K	0.2%	46
2018 Q1	$1.47M	Hold	5,376	–	–	0.19%	45
2017 Q4	$1.71M	Sell	5,376 -1,739	-24%	-$558K	0.21%	43
2017 Q3	$2.23M	Hold	7,115	–	–	0.27%	40
2017 Q2	$1.93M	Hold	7,115	–	–	0.24%	35
2017 Q1	$1.95M	Hold	7,115	–	–	0.25%	37
2016 Q4	$2.02M	Sell	7,115 -126	-2%	-$37.4K	0.26%	35
2016 Q3	$2.27M	Hold	7,241	–	–	0.29%	33
2016 Q2	$1.75M	Hold	7,241	–	–	0.22%	39
2016 Q1	$1.89M	Hold	7,241	–	–	0.23%	41
2015 Q4	$2.22M	Buy	7,241 +973	+16%	+$280K	0.25%	40
2015 Q3	$1.83M	Buy	6,268 +892	+17%	+$295K	0.21%	47
2015 Q2	$2.17M	Hold	5,376	–	–	0.24%	45
2015 Q1	$2.27M	Hold	5,376	–	–	0.27%	39
2014 Q4	$1.82M	Hold	5,376	–	–	0.2%	50
2014 Q3	$1.78M	Buy	5,376 +96	+2%	+$31.7K	0.21%	46
2014 Q2	$1.67M	Hold	5,280	–	–	0.2%	47
2014 Q1	$1.61M	Sell	5,280 -100	-2%	-$31.7K	0.2%	44
2013 Q4	$1.5M	Hold	5,380	–	–	0.19%	43
2013 Q3	$1.29M	Sell	5,380 -500	-9%	-$112K	0.17%	47
2013 Q2	$1.26M	Buy	+5,880	New	+$1.26M	0.19%	42

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cannell & Spears's BIIB Position: Q1 2026 in Review

Cannell & Spears increased its Biogen (BIIB) stake by 0.08% in Q1 2026, buying an estimated $737 and bringing the position to 5,083 shares worth $932K. The position accounts for 0.02% of the portfolio, ranked #246.

Cannell & Spears first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.27M in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Cannell & Spears held 5,083 shares of Biogen worth $932K as of Q1 2026.
Cannell & Spears bought 4 Biogen shares in Q1 2026, an estimated $737.
Biogen made up 0.02% of Cannell & Spears's portfolio in Q1 2026, its #246 holding.
Cannell & Spears first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
Cannell & Spears's Biogen position peaked at $2.27M in Q1 2015.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.